drugset
drugset / Trial / NCT04865393

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

NCT04865393 ↗

Phase 1 Completed 37 enrolled Spero Therapeutics United States Department of Defense · collab
NaSingle-groupOpen-labelOther

Summary

Evaluation of the pharmacokinetics (PK) of SPR206 in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.

Timeline

Start
2021-06-08
Primary completion
2021-12-01
Completion
2021-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject UPLEGANAN Other / unclassified 100 mg Intravenous

Indications

impaired renal function disease